Endocrinology Advisor | Extended-Release Naltrexone/Bupropion Efficacious for Weight Loss in Type 2 Diabetes Endocrinology Advisor In the study led by Raymond Plodkowski, MD, from Orexigen Therapeutics, Inc. in La Jolla, California, researchers, conducted efficacy analyses to determine weight loss and glycemic effects in patients who were considered "early responders," defined as ... |
Originally posted here:
Extended-Release Naltrexone/Bupropion Efficacious for Weight Loss in Type 2 Diabetes - Endocrinology Advisor
